Humulina Nph Kwikpen (Insulin Human (Rdna))

Humulina Nph Kwikpen is indicated for the management of blood glucose in adults and children with diabetes mellitus who need basal insulin therapy.

• Provides intermediate‑acting insulin coverage to control fasting glucose levels.
• Used as part of a basal‑bolus regimen together with rapid‑acting insulin.
• Suitable for patients with type 1 diabetes requiring long‑acting insulin.
• Suitable for patients with type 2 diabetes when oral agents are insufficient.
• Can be combined with lifestyle measures such as diet and exercise.

• Humulina Nph Kwikpen contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering endogenous glucose production. The protamine component prolongs absorption, giving an intermediate duration of action.

Adverse reactions to Humulina Nph Kwikpen may vary in frequency and severity.

Common

• Hypoglycemia (low blood sugar)
• Injection‑site pain, redness, or swelling
• Lipodystrophy (localized fat tissue changes)
• Weight gain

Serious

• Severe hypoglycemia leading to loss of consciousness
• Allergic reactions such as rash, urticaria, or anaphylaxis
• Hypokalemia (low potassium levels)

When using Humulina Nph Kwikpen, several safety considerations should be observed.

• Monitor blood glucose regularly to avoid hypoglycemia.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Educate patients on proper injection technique to minimize lipodystrophy.
• Pregnant or breastfeeding individuals should consult a healthcare professional before use.
• Store the pen according to manufacturer instructions and discard after the indicated period once opened.

Humulina Nph Kwikpen can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers, which can mask hypoglycemia symptoms.
• High‑dose corticosteroids, which may increase insulin resistance.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia.
• MAO‑inhibitors and tricyclic antidepressants, which may alter glucose metabolism.
• Diuretics, especially thiazides, that can affect potassium levels and insulin sensitivity.